ECSP045114A - CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES - Google Patents

CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES

Info

Publication number
ECSP045114A
ECSP045114A EC2004005114A ECSP045114A ECSP045114A EC SP045114 A ECSP045114 A EC SP045114A EC 2004005114 A EC2004005114 A EC 2004005114A EC SP045114 A ECSP045114 A EC SP045114A EC SP045114 A ECSP045114 A EC SP045114A
Authority
EC
Ecuador
Prior art keywords
growth hormone
human growth
chemically modified
modified human
hgh
Prior art date
Application number
EC2004005114A
Other languages
Spanish (es)
Inventor
Rory F Finn
Wei Liao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ECSP045114A publication Critical patent/ECSP045114A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una modificación química de la hormona de crecimiento humana (hGH) y a variantes agonistas de la misma mediante la cual se pueden cambiar las propiedades químicas y/o fisiológicas de la hGH. La hGH PEGilada puede tener una mayor duración de residencia en plasma, una menor velocidad de aclaramiento, mejor estabilidad, menos antigenicidad o una combinación de estas característicasThe present invention relates to a chemical modification of human growth hormone (hGH) and agonist variants thereof by which the chemical and / or physiological properties of hGH can be changed. PEGylated hGH may have a longer residence duration in plasma, a lower clearance rate, better stability, less antigenicity or a combination of these characteristics

EC2004005114A 2001-11-20 2004-05-20 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES ECSP045114A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
ECSP045114A true ECSP045114A (en) 2004-07-23

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005114A ECSP045114A (en) 2001-11-20 2004-05-20 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20070072924A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA008505B1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
AU2003210564B2 (en) * 2002-01-18 2008-10-23 Biogen Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compound
BR0314172A (en) 2002-09-09 2005-07-26 Nektar Therapeutics Al Corp Water-soluble polymer, composition, hydrate or acetal form, compound, composition, uses of compound and conjugate, and process for preparing conjugate
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
JP2007508250A (en) * 2003-10-10 2007-04-05 ノボ　ノルディスク　アクティーゼルスカブ Long acting molecules in sustained release formulations
CN103215328B (en) * 2004-01-21 2016-08-03 诺和诺德医疗保健公司 The joint of transglutaminase mediated peptide
EP1789092A2 (en) * 2004-08-31 2007-05-30 Pharmacia & Upjohn Company LLC Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
EP2284191A3 (en) 2004-12-22 2011-07-20 Ambrx, Inc. Process for the preparation of hGH
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
KR20070100299A (en) * 2004-12-22 2007-10-10 암브룩스, 인코포레이티드 Methods for expression and purification of recombinant human growth hormone
EP1850878A2 (en) 2005-02-10 2007-11-07 Novo Nordisk A/S C-terminally pegylated growth hormones
DE602006020032D1 (en) 2005-04-18 2011-03-24 Novo Nordisk As IL-21 VARIANTS
JP2009506096A (en) * 2005-08-30 2009-02-12 ノボ ノルディスク ヘルス ケア アーゲー Liquid preparation of pegylated growth hormone
EP1954710B1 (en) * 2005-11-08 2011-03-02 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
CN101448512B (en) 2005-12-14 2015-11-25 Ambrx公司 Purposes containing alpha-non-natural amino acid and the compositions of polypeptide, the method relating to alpha-non-natural amino acid and polypeptide and alpha-non-natural amino acid and polypeptide
EP2040757A2 (en) * 2006-07-07 2009-04-01 Novo Nordisk Health Care AG New protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
CN101553501A (en) 2006-10-26 2009-10-07 诺沃-诺迪斯克有限公司 IL-21 variants
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
RU2488598C2 (en) * 2008-04-03 2013-07-27 Биостид Джене Експрешен Тек. Ко., Лтд. Double-stranded polyethylene glycol modified growth hormone, preparation method and use thereof
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human growth hormone derivative linked with polyethyleneglycol, method for the preparation thereof and pharmaceutical composition comprising the same
CN102131844B (en) * 2008-07-31 2016-03-02 药华医药股份有限公司 Peptide-polymer conjugates
BRPI0917000A2 (en) 2008-08-06 2016-02-16 Novo Nordisk Healthcare Ag protein conjugates with prolonged in vivo efficacy
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
EP2331139B1 (en) * 2008-09-11 2019-04-17 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
MX2011007736A (en) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
US9511122B2 (en) 2009-12-15 2016-12-06 Ascendis Pharma Growth Disorders Division A/S Dry growth hormone composition transiently linked to a polymer carrier
WO2011089255A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011089250A2 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
EP2571896A4 (en) * 2010-05-17 2014-01-08 Cebix Inc Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
HUE064909T2 (en) 2014-11-06 2024-04-28 Pharmaessentia Corp Dosage regimen for pegylated interferon
ES2896971T3 (en) 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Forms of long-acting growth hormone administration
IL254389B2 (en) * 2015-03-11 2023-03-01 Nektar Therapeutics Conjugates of an il-7 moiety and an polymer
SG11201802180TA (en) * 2015-09-18 2018-04-27 Univ Miyazaki Long-acting adrenomedullin derivative

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE69128944T2 (en) * 1990-05-04 1998-06-25 American Cyanamid Co Stabilization of somatotropin through modification of cysteine residues
JPH06506217A (en) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE122006000003I1 (en) * 1995-09-21 2006-05-04 Genentech Inc Variants of Human Growth Hormone
ES2297889T3 (en) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. DERIVATIVES OF HORMONE OF GROWTH AND RELATED PROTEINS.
WO2000042175A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
JP2002540065A (en) * 1999-01-29 2002-11-26 アムジェン インコーポレーテッド GCSF conjugate
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
JP2004524020A (en) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス Improved growth hormone molecule

Also Published As

Publication number Publication date
CA2467731A1 (en) 2003-05-30
ZA200403907B (en) 2007-12-27
EA200700431A1 (en) 2008-02-28
HUP0500997A2 (en) 2007-11-28
OA13063A (en) 2006-11-10
AU2002356990A1 (en) 2003-06-10
EA200400565A1 (en) 2005-06-30
HRP20040448A2 (en) 2006-02-28
KR20050044858A (en) 2005-05-13
EA008505B1 (en) 2007-06-29
NO20042182L (en) 2004-08-11
PL374354A1 (en) 2005-10-17
WO2003044056A2 (en) 2003-05-30
MXPA04004809A (en) 2004-08-11
MA27544A1 (en) 2005-10-03
RS53104A (en) 2006-10-27
BR0214451A (en) 2006-05-30
TNSN04090A1 (en) 2006-06-01
CN1608079A (en) 2005-04-20
EP1453859A2 (en) 2004-09-08
WO2003044056A3 (en) 2003-08-21
GEP20063860B (en) 2006-06-26
KR20070072924A (en) 2007-07-06
JP2005525302A (en) 2005-08-25
CO5580794A2 (en) 2005-11-30
JP2006321808A (en) 2006-11-30
AP2004003050A0 (en) 2004-06-30
IS7268A (en) 2004-05-17
IL162031A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
ECSP045114A (en) CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES
LU92175I2 (en) lixisenatide
PL374178A1 (en) Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AP2003002918A0 (en) Pulmonary administration of chemically modified insulin.
DE602004017252D1 (en) Body care compositions Compositions containing structured conditioner premix
IL173299A0 (en) Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds
NO20053556D0 (en) Polymer conjugates of interferon-beta with enhanced biological potency.
AU2002329990A1 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2002245413A1 (en) Athletic clothing with sting reduction padding
NO20042172L (en) Insulin molecule with extended duration of action
MXPA03007802A (en) Composition improving age-related physiological deficits and increasing longevity.
WO2003057135A3 (en) Aqueous compositions containing metronidazole
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
AU2002351593A1 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
HK1075406A1 (en) Biologically stable liquid composition of fvIII, of vwf or of fviii/vwf complex of human origin
HK1069181A1 (en) Cyclic ketones as blocking agents
EA200400399A1 (en) METHODS OF TREATMENT OF PULMONARY DISEASES
IL175369A0 (en) Novel compound, corresponding compositions, preparation and/or treatment methods
AU2003223679A1 (en) Implantable lead with improved distal tip
DE502004010644D1 (en) FLAVORED MEDICAMENT FORMULATIONS WITH IMPROVED PHARMACEUTICAL PROPERTIES
BRPI0412803A (en) unglycosylated human alpha-fetoprotein, production methods and uses thereof
IL164195A0 (en) Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
WO2004085471A3 (en) Glp-2 derivatives
ZA200205880B (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith.
EP1581196A4 (en) Acid labile drug compositions